|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/454 | |
| A61K 31/4985 | |||
| A61K 31/7056 | |||
| A61K 45/06 | |||
| A61P 31/22 |
| (11) | Number of the document | 3318258 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17189252.4 |
| Date of filing the European patent application | 2014-03-14 | |
| (97) | Date of publication of the European application | 2018-05-09 |
| (45) | Date of publication and mention of the grant of the patent | 2020-05-13 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201361783437 P | 2013-03-14 | US |
| (72) |
BERNSTEIN, Barry M., US
DUTTA, Sandeep, US
LIU, Wei, US
PODSADECKI, Thomas J., US
CAMPBELL, Andrew L., US
MENON, Rajeev M., US
LIN, Chih-Wei, US
WANG, Tianli, US
AWNI, Walid M., US
MENSING, Sven, DE
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
|
| (54) | COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS |
| COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS |